Pronova BioPharma posted strong third quarter results, driven by robust end-user demand and consistent performance at the Sandefjord plant. In-sourcing of intermediaries has facilitated the increase of the
production forecast for 2009 to 1 400-1 500 tonnes. Positive results for the GISSI-heart failure trial were published at the European Society of Cardiology in August. Both primary endpoints were met.
